|Title:||Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS||Authors:||Park K.
|Issue Date:||2020||Publisher:||Elsevier Ltd||Journal Volume:||31||Journal Issue:||2||Start page/Pages:||191-201||Source:||Annals of Oncology||Abstract:||
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of early and locally-advanced non-small-cell lung cancer (NSCLC) was published in 2017, and covered the diagnosis, staging, management and treatment of both early stage I and II disease and locally-advanced stage III disease. At the ESMO Asia Meeting in November 2018, it was decided by both the ESMO and the Korean Society of Medical Oncology (KSMO) to convene a special face-to-face guidelines meeting in 2019 in Seoul. The aim was to adapt the ESMO 2017 guidelines to take into account potential differences related to ethnicity, cancer biology and standard practices associated with the treatment of locally-advanced, unresectable NSCLC in Asian patients. These guidelines represent the consensus opinions reached by those experts in the treatment of patients with lung cancer who represented the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and it was independent of both local current treatment practices and the treatment availability and reimbursement situations in the individual participating Asian countries. ? 2019 European Society for Medical Oncology
|ISSN:||0923-7534||DOI:||10.1016/j.annonc.2019.10.026||SDG/Keyword:||atezolizumab; carboplatin; cisplatin; durvalumab; etoposide; nivolumab; paclitaxel; pembrolizumab; pemetrexed; Vinca alkaloid; vinorelbine tartrate; Article; Asian; cancer combination chemotherapy; cancer immunotherapy; cancer radiotherapy; cancer risk; cancer screening; cancer staging; cancer survival; China; computer assisted tomography; contrast enhancement; endoscopic ultrasonography; ethnic difference; health care access; health care availability; human; India; Japan; Korea; Malaysia; median survival time; mediastinoscopy; non small cell lung cancer; nuclear magnetic resonance imaging; overall survival; personalized medicine; physical examination; positron emission tomography; practice guideline; priority journal; progression free survival; radiation dose; reimbursement; risk assessment; Singapore; Taiwan; thorax radiography; tumor ablation; tumor volume; Asia; lung tumor; non small cell lung cancer; oncology; South Korea; Asia; Carcinoma, Non-Small-Cell Lung; China; Humans; India; Japan; Lung Neoplasms; Malaysia; Medical Oncology; Republic of Korea; Taiwan
|Appears in Collections:||腫瘤醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.